The Multisystem Disorder Is Characterized by New-Onset Hypertension of 140/90 mmHg or Higher

The multisystem disorder is characterized by new-onset hypertension of 140/90 mmHg or higher after 20 weeks of gestation, accompanied by proteinuria, maternal organ dysfunction, or placental dysfunction such as fetal growth restriction.

Eclampsia involves the onset of generalized tonic-clonic seizures in a woman with preeclampsia. Additional severe complications include hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome and posterior reversible encephalopathy syndrome (PRES), a neurological condition that may develop in women with severe preeclampsia, eclampsia, or HELLP syndrome, including in the early puerperium, and which necessitates prompt brain imaging and multidisciplinary management.

Cases are classified as early-onset or late-onset using 34 weeks of gestation as the cutoff, with early-onset carrying a significantly higher risk of maternal and perinatal complications. Clinical manifestations span from isolated hypertension and proteinuria to life-threatening complications and death.

Data from a World Health Organization survey across 29 countries showed that women with preeclampsia faced an eightfold higher likelihood of developing a life-threatening complication compared to women without the disease. Across 40 low- and middle-income countries, hemorrhage and hypertensive disorders together were responsible for about one-third of maternal deaths in health facilities.

In India, the burden of preeclampsia remains high, with maternal and perinatal outcomes influenced by antenatal coverage, referral services, and uneven access to health facilities. South Asian origin is recognized as a risk factor, yet evidence from the region has remained scattered across single-center, hospital-based studies from individual countries. In New Delhi, India, a 2023 prospective study of 145 women with severe preeclampsia at less than 28 weeks of gestation reported that 29.7% had one or more major complications, 16.6% developed HELLP syndrome, and 8.3% developed eclampsia, alongside a stillbirth rate of 68.7% and 17.0% of live-born infants surviving to 28 days.

In Odisha, India, a 2022 prospective study of 63 women with eclampsia and PRES found that 19.0% experienced HELLP syndrome, 11.1% experienced placental abruption, 41.3% required NICU admission, and the neonatal death rate was 6.3%. In Biratnagar, Nepal, a 2019 prospective study of 100 women with eclampsia recorded pulmonary edema in 41%, renal failure in 6%, maternal death in 4%, and 29 perinatal deaths out of 100 with no difference by gravidity.

In Dharan, Nepal, a 2016 retrospective study of 112 women with eclampsia among 8,066 deliveries found that more than 90% were unbooked, with a maternal death rate of 5.36% and a perinatal death rate of 9%. It is not yet fully known how outcomes compare country by country across all eight South Asian nations due to this previously fragmented literature.